Showing results
1 to
15 of
1143
-
Friday, September 25, 2020
-
In this
Economics Weekly, we discuss the two positions, with the view that over the medium to longer term deflation is much less unlikely, and that while the risks are increasingly tilting toward a more rapid increase in inflation, we still do not feel that inflation is about to break out in any kind of uncontrolled manner.
-
Wednesday, September 23, 2020
-
William Blair acted as the lead financial advisor to Zywave, a portfolio company of Aurora Capital Partners, in connection with its pending sale to Clearlake Capital.
-
Wednesday, September 23, 2020
-
William Blair & Company initiated research coverage of 9 Meters Biopharma, Inc. (NMTR $0.68). Created by the integration of three companies in May 2020, 9 Meters Biopharma is a clinical-stage biotechnology company focused on therapies for unmet needs in gastrointestinal disorders.
-
Friday, September 18, 2020
-
William Blair & Company initiated research coverage of Aravive, Inc. (ARAV $5.81), a clinical-stage biotechnology company that leverages deep insights into essential cancer signaling pathways. The company’s lead asset AVB-500 completed a Phase Ib study earlier this year, and will soon enter midstage trials in ovarian and kidney cancer.
-
Friday, September 18, 2020
-
In this
Economics Weekly, we take a look at one key gauge that the Fed has increasingly used for its policy stance—the Financial Conditions Index—and assess just how much more room it has to act and what corners of the market are the most likely to be impacted.
-
Monday, September 14, 2020
-
William Blair acted as exclusive financial advisor to Insurance Technologies, LLC (Insurance Technologies), a portfolio company of NexPhase Capital, LP (NPC), an operationally focused private equity firm and sub-advisor to the Moelis Capital Partners (MCP) Opportunity Fund, in connection with its pending sale to Thomas H. Lee Partners, LP (THL).
-
Monday, September 14, 2020
-
William Blair & Company initiated research coverage of Prevail Therapeutics Inc. (PRVL $11.90), a clinical-stage company developing adeno-associated virus (AAV) gene therapies for neurodegenerative disorders of the central nervous system.
-
Friday, September 11, 2020
-
In this week’s
Economics Weekly, we once again examine the productivity question, with the conclusion that the COVID crisis has likely given productivity a huge boost that should continue for several years to come.
-
Thursday, September 10, 2020
-
William Blair & Company initiated research coverage of Duck Creek Technologies, Inc. (DCT $37.21). Duck Creek provides software-as-a-service (SaaS) based core-system solutions that property-and-casualty (P&C) insurers use to manage the full customer lifecycle.
-
Tuesday, September 8, 2020
-
William Blair has announced the opening of a new office in Singapore, expanding its presence in Asia.
-
Friday, September 4, 2020
-
William Blair & Company initiated research coverage of Vista Outdoor Inc. (VSTO $19.43), a manufacturer of outdoor and recreation consumer products.
-
Friday, September 4, 2020
-
William Blair & Company initiated research coverage of Clarus Corporation (CLAR $13.13), a leading outdoor enthusiast company, focused on the climb, ski, mountain, sport, and skincare markets.
-
Friday, September 4, 2020
-
In this
Economics Weekly, we take a look at the current inventory situation in the United States.
-
Wednesday, September 2, 2020
-
William Blair & Company initiated research coverage of Nautilus, Inc. (NLS $11.85), which designs and markets some of the most recognizable brands in the at-home fitness industry, including Nautilus, Bowflex, Schwinn, and Universal.
-
Tuesday, September 1, 2020
-
The Women's Alliance business resource group at William Blair hosted a virtual discussion with colleagues about empowering women on August 26 to mark Women's Equality Day and the 100th anniversary of the 19th Amendment guaranteeing women's U.S. constitutional right to vote.
Previous 1 2 3 4 5 ... Next